{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"43.4","upperLimit":"75.7","value":"61.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"}],"units":"Participants"}],"description":"GVHD-free survival is defined as the time from the date of PBSCT to date of events which include grade III-IV acute GVHD and systemic therapy-requiring chronic GVHD.","dispersionType":"95% Confidence Interval","groups":[{"description":"All participants will receive a conditioning regimen of Fludarabine, Melphalan and Total Body Irradiation prior to transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT)\n\nFludarabine: Fludarabine 30mg/m\\^2/day will be administered over 30-60 minutes intravenous infusion on Days -6 through -2 for a total dose of 150 mg/m\\^2\n\nMelphalan: Melphalan 70 mg/m\\^2 over 45 minutes will be administered Day -6. Melphalan dose will be calculated based on Actual Body Weight.\n\nTotal Body Irradiation: Total Body Irradiation (TBI) will be delivered at a dose of 200 centigray units (cGy)","id":"OG000","title":"Conditioning Regimen + Transplant"}],"paramType":"NUMBER","populationDescription":"Evaluable Participants","reportingStatus":"POSTED","timeFrame":"At 180 days post-transplant","title":"Percentage of Participants With Graft vs Host Disease (GVHD) Free Survival","type":"SECONDARY","unitOfMeasure":"percentage of participants"}